Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Abstract Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use. An efficacious, tolerable, and convenient PI option is needed. Methods In this singl...

Full description

Bibliographic Details
Main Authors: Man Shen, Jiajia Zhang, Ran Tang, Yuhao Wang, Xiaokai Zhan, Sibin Fan, Zhongxia Huang, Yuping Zhong, Xin Li
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Cancer Medicine
Subjects:
bortezomib
ixazomib
maintenance therapy
multiple myeloma
not undergoing transplantation
real‐world
Online Access:https://doi.org/10.1002/cam4.4313

Internet

https://doi.org/10.1002/cam4.4313

Similar Items